{"gene":"CTSL","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1996,"finding":"Crystal structure of human procathepsin L at 2.2 Å resolution revealed that the prosegment inhibits enzymatic activity through a globular N-terminal domain (three α-helices with a hydrophobic core) that packs against the enzyme surface, while the C-terminal portion occupies the substrate-binding cleft in reverse orientation to substrates.","method":"X-ray crystallography of a catalytic mutant of human procathepsin L","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure at 2.2 Å with functional interpretation of inhibitory mechanism","pmids":["8896443"],"is_preprint":false},{"year":1998,"finding":"The serpin SCCA1 acts as a cross-class inhibitor of cathepsins K, L, and S at 1:1 stoichiometry with second-order rate constants ≥1×10⁵ M⁻¹ s⁻¹, forming stable covalent-like complexes via its reactive site loop, analogous to serpin–serine protease interactions.","method":"Kinetic analysis (in vitro enzyme inhibition assays) and SDS-PAGE detection of stable SCCA1–cathepsin complexes","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with rigorous kinetic characterization","pmids":["9548757"],"is_preprint":false},{"year":2000,"finding":"Secreted cathepsin L is responsible for generating endostatin from collagen XVIII with the predicted N-terminus at moderately acidic pH resembling the pericellular tumor milieu; metalloproteases produce larger fragments in a parallel pathway.","method":"Conditioned medium proteolysis assay, N-terminal amino acid sequencing, use of cathepsin L-specific inhibitors","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — cell-free reconstitution identifying CTSL as sufficient protease for endostatin generation with N-terminal sequencing validation","pmids":["10716919"],"is_preprint":false},{"year":2004,"finding":"A cathepsin L isoform lacking a signal peptide localizes to the nucleus during the G1-S transition and proteolytically processes the CDP/Cux transcription factor, regulating cell cycle progression; nuclear trafficking involves translation initiation at downstream AUG codons.","method":"Immunofluorescence imaging, activity-based probes for nuclear CTSL, ectopic expression in Cat L⁻/⁻ cells, in situ CDP/Cux processing assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including activity-based probes, genetic knockout rescue, and live-cell imaging establishing both localization and substrate","pmids":["15099520"],"is_preprint":false},{"year":2005,"finding":"Cathepsin L is required for SARS-CoV infection of ACE2-expressing cells; cathepsin L inhibitors block infection by SARS-CoV and retrovirus pseudotyped with SARS-CoV spike protein, and exogenous cathepsin L substantially enhances SARS-CoV S protein-mediated entry. HCoV-NL63, which uses the same ACE2 receptor, does not require cathepsin L, demonstrating distinct entry mechanisms for two ACE2-using coronaviruses.","method":"Pseudovirus infection assays, pharmacological inhibition of cathepsin L, exogenous cathepsin L expression in target cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (inhibitors, overexpression, pseudovirus) in same study, replicated with related PMID 16081529","pmids":["16339146","16081529"],"is_preprint":false},{"year":2005,"finding":"Cathepsin L inhibitors block SARS-CoV infection; in a cell-free membrane fusion system, receptor engagement followed by cathepsin L proteolysis is sufficient to activate SARS-CoV spike-mediated membrane fusion, defining a unique three-step entry mechanism: receptor binding → conformational change → cathepsin L cleavage in endosomes.","method":"Cell-free membrane fusion assay, pharmacological inhibition of cathepsin L, lysosomotropic agents, SARS-CoV S protease treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — cell-free reconstitution demonstrating cathepsin L is sufficient for spike activation and membrane fusion","pmids":["16081529"],"is_preprint":false},{"year":2005,"finding":"Cathepsin L is essential for endothelial progenitor cell (EPC)-mediated neovascularization: CathL-deficient mice showed impaired recovery after hind limb ischemia; CathL-deficient EPCs failed to home to ischemic tissue or promote neovascularization; forced CathL expression in mature endothelial cells conferred invasive and neovascularization capacity.","method":"CathL knockout mouse model, hind limb ischemia model, EPC infusion, in vitro matrix degradation/invasion assays, forced expression in endothelial cells","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function mouse genetics plus gain-of-function rescue with defined phenotypic readouts","pmids":["15665831"],"is_preprint":false},{"year":2008,"finding":"Cathepsin L activates SARS-CoV spike protein membrane fusion function by cleaving the spike at the S1/S2 boundary region (upstream of the fusion peptide), mirroring where furin cleaves in other coronaviruses, thereby separating the receptor-binding from the fusion subunit.","method":"Cell-based fusion assays, cathepsin L cleavage mapping of spike protein truncation mutants","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1–2 — direct mapping of cleavage site with functional fusion readout","pmids":["18562523"],"is_preprint":false},{"year":2009,"finding":"Cytosolic cathepsin L cleaves essential regulators of podocyte actin dynamics, resulting in a motile podocyte phenotype and proteinuria, establishing CTSL as an enzymatic driver of podocyte dysfunction.","method":"Review synthesizing cell biological experiments including subcellular fractionation, CTSL activity assays, and podocyte actin dynamics readouts","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2–3 — synthesis of experimental findings from multiple studies; direct in-cell enzymatic evidence cited","pmids":["19924101"],"is_preprint":false},{"year":2012,"finding":"A functional promoter variant C-171A (rs3118869) disrupts a xenobiotic response element (XRE) in the CTSL1 proximal promoter; AHR:ARNT complex with its ligand dioxin augments CTSL1 transcription, and the C-171A allele modulates this response, with genotype predicting blood pressure in two independent cohorts.","method":"Promoter/luciferase reporter transfection, co-expression of AHR:ARNT with dioxin, re-sequencing of CTSL1 locus, association analysis","journal":"Journal of hypertension","confidence":"Medium","confidence_rationale":"Tier 2 — transfection reporter assay with mutagenesis and receptor co-expression, single lab","pmids":["22871890"],"is_preprint":false},{"year":2020,"finding":"SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, and cathepsin L is critical for this entry process, as established using the SARS-CoV-2 S protein pseudovirus system.","method":"SARS-CoV-2 S pseudovirus infection assay, pharmacological inhibition (PIKfyve, TPC2, cathepsin L inhibitors)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — pseudovirus system with pharmacological inhibitors, highly cited (2296 citations), replicated concept","pmids":["32221306"],"is_preprint":false},{"year":2021,"finding":"CTSL cleaves the SARS-CoV-2 spike protein and enhances virus entry; circulating CTSL is elevated in COVID-19 patients; SARS-CoV-2 pseudovirus infection increases CTSL expression in human cells and humanized ACE2-transgenic mice; CTSL overexpression enhances pseudovirus infection while knockdown reduces it; amantadine inhibits CTSL activity and prevents infection in vitro and in vivo.","method":"Pseudovirus infection assays, CTSL overexpression/knockdown, CTSL inhibitor treatment in vivo (ACE2-transgenic mice), ELISA measurement of circulating CTSL in patients","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (overexpression, knockdown, inhibitors, in vivo mouse model) with direct cleavage assay","pmids":["33774649"],"is_preprint":false},{"year":2022,"finding":"In vivo Cas13d-mediated knockdown of lung Ctsl mRNA via a nanosystem prevents and treats SARS-CoV-2 infection in mice, extending survival of lethally infected mice and reducing lung viral burden, proinflammatory cytokines, and pulmonary inflammation.","method":"CRISPR-Cas13d mRNA knockdown delivered by nanosystem in vivo; mouse SARS-CoV-2 infection model; viral burden quantification; cytokine measurement","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo loss-of-function with defined phenotypic readouts, therapeutic rescue experiment","pmids":["35879545"],"is_preprint":false},{"year":2024,"finding":"SARS-CoV-2 spike protein treatment of HeLa cells and iPSC-derived alveolarspheres induces upregulation of cathepsin L mRNA and protein levels in a time-dependent manner and increases cathepsin L promoter activity; knockout of cathepsin L reduces spike protein internalization, confirming a bidirectional relationship between CTSL and SARS-CoV-2 spike entry.","method":"Recombinant spike protein treatment, qRT-PCR, Western blot, CTSL promoter-reporter assay, CTSL knockout cell lines, spike protein internalization assay","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods including KO and promoter assay, single lab","pmids":["38971996"],"is_preprint":false},{"year":2025,"finding":"Legumain is required for processing of cathepsin L from single-chain to two-chain (mature) form; in legumain-deficient cells, CTSL remains in its single-chain form and nuclear CTSL levels are reduced in cell types where the double-chain form predominates in the nucleus. N-terminomics (NICE pipeline) identified putative nuclear substrates of CTSL involved in cell proliferation, cell cycle regulation, inflammation, and ribosomal biogenesis.","method":"Legumain-knockout (LGMN⁻/⁻) cells, activity-based probes (chemical), immunoblots, N-terminomics pipeline (NICE)","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — chemical activity-based probes + genetic KO + proteomics pipeline; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.08.17.670765"],"is_preprint":true},{"year":2025,"finding":"CTSL directly binds PDK1 in HNSCC cells, blocks NEDD4L-mediated ubiquitination of PDK1 (a non-proteolytic scaffolding function), thereby stabilizing PDK1, sustaining AKT phosphorylation, and increasing PD-L1 expression on tumor cells, driving immune evasion.","method":"Co-immunoprecipitation, ubiquitination assays, xenograft and immunocompetent mouse models, anti-PD-1 combination therapy","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2–3 — reciprocal Co-IP with functional ubiquitination assay and in vivo validation, single lab","pmids":["40961907"],"is_preprint":false},{"year":2025,"finding":"USP20 deubiquitinates and stabilizes CTSL protein in HNSCC, competing with STUB1 which promotes CTSL ubiquitination and degradation; USP20-mediated CTSL stabilization drives epithelial-to-mesenchymal transition, cancer stem cell renewal, and chemoresistance.","method":"Broad-spectrum deubiquitinase inhibitor screen, mass spectrometry identification of USP20, confocal colocalization, Co-IP, ubiquitination assays, in vitro and in vivo tumor models","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (MS, Co-IP, ubiquitination assay, in vivo), single lab","pmids":["41261048"],"is_preprint":false},{"year":2025,"finding":"Nervous system-specific double knockout of CtsB and CtsL in mice causes selective loss of Purkinje cells (phospholipase C β4-positive, Zebrin II-negative) in cerebellar striped patterns, accumulation of ubiquitin-positive structures in perikarya and axons, reduction in synaptic vesicles, and neuronal loss in thalamic nuclei, demonstrating that CtsL (with CtsB) is essential for autophagy-lysosomal degradation in cerebellar Purkinje cells.","method":"Conditional double-knockout mice (Nestin-Cre; CTSBflox/flox; CTSLflox/flox), immunohistochemistry, electron microscopy, behavioral tests","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with multiple orthogonal readouts (behavior, histology, EM) demonstrating cell-type-specific requirement","pmids":["40320169"],"is_preprint":false},{"year":2025,"finding":"Drug-induced nuclear trafficking of CTSL (via KPNB1-mediated import and CRM1/XPO1-mediated export regulation) is critical for the DNA damage response in ovarian cancer cells; nuclear CTSL mediates cell cycle arrest and apoptosis; CTSL knockdown confers resistance to the clofarabine + olaparib combination.","method":"CTSL knockdown, nuclear fractionation, KPNB1 import assay, CRM1 inhibition, patient-derived ovarian ascites ex vivo, PDX xenograft models","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cell models and in vivo PDX validation; preprint, not yet peer-reviewed","pmids":["39868276"],"is_preprint":true},{"year":1991,"finding":"Lysosomal cathepsins including cathepsin L are abnormally distributed in Alzheimer disease brains, accumulating in enlarged lysosomes of cortical neurons and appearing extracellularly in senile plaques, suggesting that lysosome dysfunction and liberation of cathepsins from degenerating neurons may contribute to amyloid precursor protein proteolysis and β-amyloid formation.","method":"Immunocytochemistry, immunoelectron microscopy, enzyme histochemistry in human brain tissue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 — localization by immunohistochemistry with functional inference; replicated for multiple cathepsins","pmids":["1837142"],"is_preprint":false},{"year":2017,"finding":"Transgenic overexpression of human CTSL in PyMT breast cancer mice increases metastatic burden and produces a distinct metastatic proteome signature compared with CTSB overexpression, including elevated saposin and granulin levels, demonstrating that CTSL has unique downstream substrate targets in vivo distinct from cathepsin B.","method":"LC-MS/MS quantitative proteomics of lung metastases from transgenic mice, hierarchical clustering","journal":"Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 — quantitative in vivo proteomics with three biological replicates and non-supervised clustering; single lab","pmids":["29187882"],"is_preprint":false}],"current_model":"CTSL encodes a lysosomal cysteine protease (cathepsin L) that is synthesized as an inactive proenzyme inhibited by its prosegment (established by crystal structure); it is activated by legumain-dependent processing to a two-chain mature form. In addition to its canonical lysosomal degradative role, CTSL is secreted at acidic pH to generate endostatin from collagen XVIII, traffics to the nucleus during G1-S transition (via a signal-peptide-deficient isoform imported through KPNB1) where it cleaves the CDP/Cux transcription factor to regulate cell cycle progression, is regulated post-translationally by USP20-mediated deubiquitination (stabilizing it) and STUB1-mediated ubiquitination (targeting it for degradation), and exerts non-proteolytic scaffolding functions by binding PDK1 to block NEDD4L-mediated ubiquitination, thereby sustaining AKT-PD-L1 signaling. In the context of coronavirus infection, CTSL is the endosomal protease that cleaves SARS-CoV/SARS-CoV-2 spike protein at the S1/S2 boundary to activate membrane fusion and virus entry, and SARS-CoV-2 spike protein in turn upregulates CTSL expression. CTSL is also required for endothelial progenitor cell-mediated neovascularization through matrix degradation, and for autophagy-lysosomal homeostasis in cerebellar Purkinje cells."},"narrative":{"teleology":[{"year":1991,"claim":"Early evidence that cathepsin L redistributes from lysosomes in disease states established that CTSL is not confined to a housekeeping lysosomal role but may contribute to neurodegeneration through aberrant localization and extracellular release.","evidence":"Immunocytochemistry and immunoelectron microscopy of Alzheimer disease brain tissue","pmids":["1837142"],"confidence":"Medium","gaps":["Correlative localization only; no causal evidence that CTSL itself drives amyloid pathology","No loss-of-function or gain-of-function test in neurodegeneration models at this stage"]},{"year":1996,"claim":"The crystal structure of procathepsin L resolved how the prosegment inhibits enzymatic activity, providing a structural basis for understanding zymogen activation and the molecular switch controlling CTSL protease function.","evidence":"X-ray crystallography of catalytic-mutant human procathepsin L at 2.2 Å resolution","pmids":["8896443"],"confidence":"High","gaps":["Structure did not reveal which protease(s) remove the prosegment in vivo","No information on how differential isoforms or trafficking alter activation"]},{"year":1998,"claim":"Identification of SCCA1 as a cross-class serpin inhibitor of cathepsin L defined an endogenous regulatory axis controlling CTSL activity at 1:1 stoichiometry with kinetics rivaling classical serpin–serine protease pairs.","evidence":"In vitro kinetic analysis and SDS-PAGE detection of stable SCCA1–cathepsin L complexes","pmids":["9548757"],"confidence":"High","gaps":["Physiological context of SCCA1–CTSL interaction in specific tissues not established","Whether SCCA1 inhibits nuclear or secreted CTSL pools was not tested"]},{"year":2000,"claim":"Demonstration that secreted cathepsin L generates endostatin from collagen XVIII at acidic pH established an extracellular, anti-angiogenic substrate-processing role distinct from lysosomal housekeeping.","evidence":"Conditioned medium proteolysis assay with cathepsin L-specific inhibitors and N-terminal sequencing of the product","pmids":["10716919"],"confidence":"High","gaps":["In vivo relevance of CTSL-generated endostatin versus metalloprotease-generated fragments not resolved","Tumor microenvironment pH dependence not directly measured in situ"]},{"year":2004,"claim":"Discovery that a signal-peptide-deficient CTSL isoform localizes to the nucleus during G1-S and cleaves CDP/Cux revealed a moonlighting nuclear protease function regulating cell cycle gene expression, fundamentally expanding the functional repertoire of CTSL beyond lysosomes.","evidence":"Activity-based probes, immunofluorescence, and CDP/Cux processing assay in CathL-knockout and rescue cells","pmids":["15099520"],"confidence":"High","gaps":["Full spectrum of nuclear substrates unknown at this point","Mechanism of nuclear import not yet identified"]},{"year":2005,"claim":"Multiple studies established CTSL as the critical endosomal protease for SARS-CoV spike-mediated entry, with a cell-free reconstitution proving that receptor binding followed by CTSL cleavage is sufficient to trigger membrane fusion—defining a unique three-step entry mechanism.","evidence":"Pseudovirus infection assays, exogenous CTSL expression, pharmacological inhibition, and cell-free membrane fusion reconstitution","pmids":["16339146","16081529"],"confidence":"High","gaps":["Precise cleavage site on SARS-CoV spike not yet mapped","Relative contribution of CTSL versus cathepsin B in different cell types not resolved"]},{"year":2005,"claim":"In vivo loss-of-function studies showed that cathepsin L is essential for endothelial progenitor cell homing and neovascularization after ischemia, establishing a non-redundant role in tissue repair through matrix degradation.","evidence":"CathL-knockout mice, hind limb ischemia model, EPC infusion, and forced CTSL expression in endothelial cells","pmids":["15665831"],"confidence":"High","gaps":["Specific extracellular matrix substrates cleaved by CTSL in this context not identified","Whether CTSL acts cell-autonomously or through paracrine substrate release not distinguished"]},{"year":2008,"claim":"Mapping the CTSL cleavage site on SARS-CoV spike to the S1/S2 boundary resolved where the protease acts, showing it separates the receptor-binding and fusion subunits analogously to furin cleavage in other coronaviruses.","evidence":"Cathepsin L cleavage mapping using spike truncation mutants with cell-based fusion readout","pmids":["18562523"],"confidence":"High","gaps":["Whether the same site is used for SARS-CoV-2 spike was not yet tested","Structural basis for CTSL recognition of the spike cleavage site not determined"]},{"year":2020,"claim":"Extension of the SARS-CoV paradigm to SARS-CoV-2 confirmed that cathepsin L is critical for endosomal entry of the pandemic coronavirus, validating CTSL as a host-directed therapeutic target.","evidence":"SARS-CoV-2 S pseudovirus infection assays with cathepsin L inhibitors in 293/hACE2 cells","pmids":["32221306"],"confidence":"High","gaps":["Pseudovirus system may not fully recapitulate live virus biology","Cell-type-specific dependence (e.g. TMPRSS2 co-expression) not fully parsed"]},{"year":2021,"claim":"Bidirectional regulation was uncovered: SARS-CoV-2 spike upregulates CTSL expression, and elevated circulating CTSL in COVID-19 patients creates a positive feedback loop enhancing viral entry, validated by in vivo amantadine inhibition.","evidence":"Pseudovirus assays, CTSL overexpression/knockdown, ELISA in patient sera, ACE2-transgenic mouse infection with amantadine treatment","pmids":["33774649"],"confidence":"High","gaps":["Mechanism by which spike upregulates CTSL transcription not defined","Amantadine's specificity for CTSL versus off-target effects not fully resolved"]},{"year":2022,"claim":"In vivo Cas13d-mediated knockdown of Ctsl mRNA prevented and treated SARS-CoV-2 infection in mice, providing genetic proof-of-concept for CTSL as a therapeutic target beyond pharmacological inhibition.","evidence":"CRISPR-Cas13d nanosystem delivery to mouse lungs, live SARS-CoV-2 challenge, survival and viral burden quantification","pmids":["35879545"],"confidence":"High","gaps":["Long-term safety and off-target effects of Ctsl knockdown in lung not assessed","Whether compensatory cathepsins are upregulated not examined"]},{"year":2017,"claim":"Transgenic CTSL overexpression in breast cancer mice produced a metastatic proteome signature distinct from cathepsin B, demonstrating that CTSL has unique in vivo substrate specificity relevant to metastasis.","evidence":"LC-MS/MS quantitative proteomics of lung metastases from CTSL-transgenic PyMT mice","pmids":["29187882"],"confidence":"Medium","gaps":["Direct cleavage of identified substrates (saposin, granulin) by CTSL not biochemically verified","Whether the metastatic phenotype is protease-activity-dependent was not tested"]},{"year":2024,"claim":"Detailed promoter analysis confirmed that SARS-CoV-2 spike directly increases CTSL promoter activity and that CTSL knockout reduces spike internalization, mechanistically closing the positive feedback loop between spike and CTSL.","evidence":"Spike protein treatment, CTSL promoter-reporter assay, CTSL knockout cell lines, iPSC-derived alveolarspheres","pmids":["38971996"],"confidence":"Medium","gaps":["Transcription factor mediating spike-induced CTSL promoter activation not identified","Single lab; independent replication needed"]},{"year":2025,"claim":"Post-translational regulation of CTSL was elucidated: USP20 deubiquitinates and stabilizes CTSL while STUB1 promotes its ubiquitination and degradation, with this balance driving EMT and chemoresistance in HNSCC.","evidence":"DUB inhibitor screen, mass spectrometry, Co-IP, ubiquitination assays, in vivo tumor models","pmids":["41261048"],"confidence":"Medium","gaps":["Ubiquitination sites on CTSL not mapped","Whether USP20/STUB1 regulation operates in non-cancer contexts unknown"]},{"year":2025,"claim":"A non-proteolytic scaffolding function was discovered: CTSL binds PDK1 and blocks NEDD4L-mediated ubiquitination to sustain AKT–PD-L1 signaling, revealing a protease-independent mechanism for immune evasion in HNSCC.","evidence":"Reciprocal Co-IP, ubiquitination assays, xenograft and immunocompetent mouse models with anti-PD-1 therapy","pmids":["40961907"],"confidence":"Medium","gaps":["Whether the scaffolding function requires a catalytically dead form or coexists with active enzyme not resolved","Generalizability beyond HNSCC not tested"]},{"year":2025,"claim":"Conditional double knockout of CtsB and CtsL in the nervous system demonstrated that CTSL is essential for autophagy-lysosomal homeostasis in cerebellar Purkinje cells, with cell-type-selective vulnerability (Zebrin II-negative, PLCβ4-positive neurons).","evidence":"Nestin-Cre conditional double-knockout mice, immunohistochemistry, electron microscopy, behavioral testing","pmids":["40320169"],"confidence":"High","gaps":["Individual contribution of CTSL versus CTSB cannot be separated in the double knockout","Whether CTSL protects through specific substrate cleavage or bulk autophagosome clearance is not defined"]},{"year":2025,"claim":"Legumain was identified as the protease required for processing single-chain CTSL to the two-chain mature form, and N-terminomics identified putative nuclear CTSL substrates involved in proliferation, cell cycle, and ribosomal biogenesis, expanding the nuclear substrate repertoire. (preprint)","evidence":"(preprint) Legumain-knockout cells, activity-based probes, immunoblots, NICE N-terminomics pipeline","pmids":["bio_10.1101_2025.08.17.670765"],"confidence":"Medium","gaps":["Preprint; not yet peer-reviewed","Identified nuclear substrates are putative; direct cleavage validation required","Whether single-chain CTSL is catalytically active in the nucleus not tested"]},{"year":2025,"claim":"Drug-induced nuclear CTSL import via KPNB1 was shown to mediate DNA damage response and apoptosis in ovarian cancer, and CTSL knockdown conferred drug resistance, identifying the nuclear import pathway and a therapeutic vulnerability. (preprint)","evidence":"(preprint) CTSL knockdown, nuclear fractionation, KPNB1 import assay, CRM1 inhibition, PDX models","pmids":["39868276"],"confidence":"Medium","gaps":["Preprint; not yet peer-reviewed","Whether CTSL acts on DNA damage repair substrates directly or indirectly not resolved","Generalizability beyond clofarabine/olaparib combination not tested"]},{"year":null,"claim":"Major open questions include: the full catalog of nuclear CTSL substrates, the structural basis for CTSL's non-proteolytic scaffolding of PDK1, whether the CTSL ubiquitination-deubiquitination regulatory circuit (USP20/STUB1) operates broadly beyond HNSCC, and the individual contribution of CTSL versus CTSB to Purkinje cell survival.","evidence":"","pmids":[],"confidence":"Low","gaps":["No comprehensive nuclear substrate validation exists","Structural basis of CTSL–PDK1 scaffolding interaction not determined","Individual CTSL versus CTSB neuronal functions require single-knockout conditional models"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,3,4,5,7,8,11]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3,7,8]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,1,17,19]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,14,18]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4,5,10,11]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,14,16]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,5,10,11,12]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,5,10,11,12,15,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[10]}],"complexes":[],"partners":["SERPINB3","PDK1","NEDD4L","USP20","STUB1","KPNB1","LGMN","CUX1"],"other_free_text":[]},"mechanistic_narrative":"Cathepsin L (CTSL) is a lysosomal cysteine endopeptidase with broad roles in protein turnover, extracellular matrix remodeling, cell cycle regulation, viral entry, and neuronal homeostasis. Synthesized as an inactive proenzyme whose prosegment occupies the active-site cleft in reverse orientation to block catalysis [PMID:8896443], CTSL is activated by legumain-dependent processing to a two-chain mature form and traffics not only to lysosomes but also to the nucleus via a signal-peptide-deficient isoform imported through KPNB1, where it cleaves the CDP/Cux transcription factor to promote G1-S progression [PMID:15099520, PMID:39868276]. CTSL is the principal endosomal protease that cleaves the SARS-CoV and SARS-CoV-2 spike proteins at the S1/S2 boundary to activate membrane fusion and viral entry, a function validated by pharmacological inhibition, genetic knockout, and in vivo Cas13d-mediated knockdown [PMID:16081529, PMID:32221306, PMID:35879545]. Beyond its proteolytic activities—including secreted cleavage of collagen XVIII to generate endostatin [PMID:10716919] and regulation of podocyte actin dynamics [PMID:19924101]—CTSL exerts a non-proteolytic scaffolding function by binding PDK1 to block NEDD4L-mediated ubiquitination, sustaining AKT–PD-L1 signaling in head and neck cancer [PMID:40961907]."},"prefetch_data":{"uniprot":{"accession":"P07711","full_name":"Procathepsin L","aliases":["Cathepsin L1","Major excreted protein","MEP"],"length_aa":333,"mass_kda":37.6,"function":"Thiol protease important for the overall degradation of proteins in lysosomes (Probable). Plays a critical for normal cellular functions such as general protein turnover, antigen processing and bone remodeling. Involved in the solubilization of cross-linked TG/thyroglobulin and in the subsequent release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen (By similarity). In neuroendocrine chromaffin cells secretory vesicles, catalyzes the prohormone proenkephalin processing to the active enkephalin peptide neurotransmitter (By similarity). In thymus, regulates CD4(+) T cell positive selection by generating the major histocompatibility complex class II (MHCII) bound peptide ligands presented by cortical thymic epithelial cells. Also mediates invariant chain processing in cortical thymic epithelial cells (By similarity). Major elastin-degrading enzyme at neutral pH. Accumulates as a mature and active enzyme in the extracellular space of antigen presenting cells (APCs) to regulate degradation of the extracellular matrix in the course of inflammation (By similarity). Secreted form generates endostatin from COL18A1 (PubMed:10716919). Critical for cardiac morphology and function. Plays an important role in hair follicle morphogenesis and cycling, as well as epidermal differentiation (By similarity). Required for maximal stimulation of steroidogenesis by TIMP1 (By similarity) (Microbial infection) In cells lacking TMPRSS2 expression, facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via a slow acid-activated route with the proteolysis of coronavirus spike (S) glycoproteins in lysosome for entry into host cell (PubMed:16339146, PubMed:18562523, PubMed:32142651, PubMed:32221306, PubMed:37990007). Proteolysis within lysosomes is sufficient to activate membrane fusion by coronaviruses SARS-CoV and EMC (HCoV-EMC) S as well as Zaire ebolavirus glycoproteins (PubMed:16081529, PubMed:18562523, PubMed:26953343) Functions in the regulation of cell cycle progression through proteolytic processing of the CUX1 transcription factor (PubMed:15099520). Translation initiation at downstream start sites allows the synthesis of isoforms that are devoid of a signal peptide and localize to the nucleus where they cleave the CUX1 transcription factor and modify its DNA binding properties (PubMed:15099520)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P07711/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CTSL","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CTSL","total_profiled":1310},"omim":[{"mim_id":"617609","title":"NEPHROTIC SYNDROME, TYPE 15; NPHS15","url":"https://www.omim.org/entry/617609"},{"mim_id":"610008","title":"ARYLSULFATASE G; ARSG","url":"https://www.omim.org/entry/610008"},{"mim_id":"607948","title":"MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607948"},{"mim_id":"607311","title":"PROGESTERONE RECEPTOR; PGR","url":"https://www.omim.org/entry/607311"},{"mim_id":"606382","title":"MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAINS-CONTAINING, 2; MAGI2","url":"https://www.omim.org/entry/606382"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"placenta","ntpm":529.1}],"url":"https://www.proteinatlas.org/search/CTSL"},"hgnc":{"alias_symbol":["FLJ31037"],"prev_symbol":["CTSL1"]},"alphafold":{"accession":"P07711","domains":[{"cath_id":"3.90.70.10","chopping":"88-331","consensus_level":"high","plddt":96.2624,"start":88,"end":331},{"cath_id":"1.10.287","chopping":"24-71","consensus_level":"high","plddt":95.6065,"start":24,"end":71}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P07711","model_url":"https://alphafold.ebi.ac.uk/files/AF-P07711-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P07711-F1-predicted_aligned_error_v6.png","plddt_mean":93.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CTSL","jax_strain_url":"https://www.jax.org/strain/search?query=CTSL"},"sequence":{"accession":"P07711","fasta_url":"https://rest.uniprot.org/uniprotkb/P07711.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P07711/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P07711"}},"corpus_meta":[{"pmid":"35879545","id":"PMC_35879545","title":"Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35879545","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33933142","id":"PMC_33933142","title":"The lnc-CTSLP8 upregulates CTSL1 as a competitive endogenous RNA and promotes ovarian cancer metastasis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33933142","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32835700","id":"PMC_32835700","title":"Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32835700","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35414771","id":"PMC_35414771","title":"COVID-19 receptor and malignant cancers: Association of CTSL expression with susceptibility to SARS-CoV-2.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35414771","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35941174","id":"PMC_35941174","title":"A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35941174","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15932404","id":"PMC_15932404","title":"SNP analysis of AMY2 and CTSL genes in Litopenaeus vannamei and Penaeus monodon shrimp.","date":"2005","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15932404","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33231569","id":"PMC_33231569","title":"Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33231569","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22871890","id":"PMC_22871890","title":"Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure.","date":"2012","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/22871890","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29187882","id":"PMC_29187882","title":"Proteomic analysis of lung metastases in a murine breast cancer model reveals divergent influence of CTSB and CTSL overexpression.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29187882","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34807310","id":"PMC_34807310","title":"Expressions and significances of CTSL, the target of COVID-19 on GBM.","date":"2021","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34807310","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20374908","id":"PMC_20374908","title":"Association between cathepsin L (CTSL) and cathepsin S (CTSS) polymorphisms and meat production and carcass traits in Italian Large White pigs.","date":"2010","source":"Meat science","url":"https://pubmed.ncbi.nlm.nih.gov/20374908","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35155389","id":"PMC_35155389","title":"Comprehensive and Integrative Analysis of Two Novel SARS-CoV-2 Entry Associated Proteases CTSB and CTSL in Healthy Individuals and Cancer Patients.","date":"2022","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35155389","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40058477","id":"PMC_40058477","title":"Astragalus injection inhibits the growth of osteosarcoma by activating cytotoxic T lymphocyte and targeting CTSL.","date":"2025","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40058477","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36504894","id":"PMC_36504894","title":"Methionine deprivation inhibits glioma growth through downregulation of CTSL.","date":"2022","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36504894","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11978977","id":"PMC_11978977","title":"Characterization and comparative mapping of the porcine CTSL gene indicates a novel synteny between HSA9q21-->q22 and SSC10q11-->q12.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11978977","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39893643","id":"PMC_39893643","title":"CTSL Promotes Autophagy in Laryngeal Cancer Through the IL6-JAK-STAT3 Signalling Pathway.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39893643","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21598116","id":"PMC_21598116","title":"Association between polymorphisms in cathepsin and cystatin genes with meat production and carcass traits in Italian Duroc pigs: confirmation of the effects of a cathepsin L (CTSL) gene marker.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21598116","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37738239","id":"PMC_37738239","title":"Large-scale whole exome sequencing studies identify two genes,CTSL and APOE, associated with lung cancer.","date":"2023","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37738239","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40961907","id":"PMC_40961907","title":"Targeting lysosomal protease CTSL promotes anti-tumor immunity and sensitizes HNSCC to PD-1 blockade by stabilizing PDK1 and activating Akt-PD-L1 axis.","date":"2025","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40961907","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26374357","id":"PMC_26374357","title":"Association Between Polymorphism in the Human Cathepsin L (CTSL1) Promoter with Hypertension in the Uygur, Kazak and Han Populations in China.","date":"2015","source":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","url":"https://pubmed.ncbi.nlm.nih.gov/26374357","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40275325","id":"PMC_40275325","title":"CTSL-2 upon specifically recognizing Vibrio splendidus directly cleaves complement C3 to promote the bacterial phagocytosis and degradation in oyster.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/40275325","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39868276","id":"PMC_39868276","title":"Role of drug induced nuclear CTSL (nCTSL) in DNA damage response in cancer- therapeutic implications.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39868276","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41261048","id":"PMC_41261048","title":"USP20 competitively binds to STUB1 to enhance CTSL expression and promote epithelial-mesenchymal transition in head and neck squamous cell carcinoma.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41261048","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38971996","id":"PMC_38971996","title":"SARS-CoV-2 Spike Protein Induces Time-Dependent CTSL Upregulation in HeLa Cells and Alveolarspheres.","date":"2024","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38971996","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40320169","id":"PMC_40320169","title":"Uncovering the Unique Roles of Cathepsins B and L in Purkinje Cells Using Nervous System-Specific CTSB and CTSL Double-Deficient Mice.","date":"2025","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40320169","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39864211","id":"PMC_39864211","title":"High expression of SERPINE1 and CTSL in keratinocytes in pressure injury caused by ischemia-reperfusion injury.","date":"2025","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/39864211","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41807810","id":"PMC_41807810","title":"Pinostrobin attenuates microglia-mediated neuroinflammation after subarachnoid hemorrhage through modulation of the MYC-CTSL signaling axis.","date":"2026","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41807810","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27792712","id":"PMC_27792712","title":"[Level of expression of gene CTSL and its correlation with natural killer T-Cells in mexican pediatric patients with recent-onset type 1 diabetes].","date":"2016","source":"Gaceta medica de Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/27792712","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.17.670765","title":"Legumain drives processing of cathepsins and nuclear localisation of cathepsin L","date":"2025-08-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.17.670765","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.04.08.25325108","title":"Brainstem Reduction and Deformation in the 4th Ventricle Cerebellar Peduncles in Long COVID Patients: Insights into Neuroinflammatory Sequelae and “Broken Bridge Syndrome”","date":"2025-04-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.08.25325108","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.19.24315794","title":"Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination","date":"2024-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.19.24315794","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.12.657772","title":"A single-cell fixed RNA profiling of liver fibrosis progression and regression reveals SEMA4D and LMCD1 as key mediators of fibrogenesis","date":"2025-06-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.12.657772","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"32221306","id":"PMC_32221306","title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32221306","citation_count":2296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12754519","id":"PMC_12754519","title":"Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12754519","citation_count":1176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16081529","id":"PMC_16081529","title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16081529","citation_count":839,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33774649","id":"PMC_33774649","title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33774649","citation_count":412,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10716919","id":"PMC_10716919","title":"Secreted cathepsin L generates endostatin from collagen XVIII.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10716919","citation_count":373,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8896443","id":"PMC_8896443","title":"Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8896443","citation_count":316,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15099520","id":"PMC_15099520","title":"A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15099520","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16339146","id":"PMC_16339146","title":"SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16339146","citation_count":299,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23536651","id":"PMC_23536651","title":"TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23536651","citation_count":268,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1837142","id":"PMC_1837142","title":"Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1837142","citation_count":262,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21900206","id":"PMC_21900206","title":"A directed protein interaction network for investigating intracellular signal transduction.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21900206","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32512386","id":"PMC_32512386","title":"Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32512386","citation_count":252,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15174051","id":"PMC_15174051","title":"An investigation into the human serum \"interactome\".","date":"2004","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/15174051","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9548757","id":"PMC_9548757","title":"Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9548757","citation_count":242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15665831","id":"PMC_15665831","title":"Cathepsin L is required for endothelial progenitor cell-induced neovascularization.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15665831","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18562523","id":"PMC_18562523","title":"Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide.","date":"2008","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/18562523","citation_count":232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19924101","id":"PMC_19924101","title":"Proteinuria: an enzymatic disease of the podocyte?","date":"2009","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/19924101","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18997,"output_tokens":2868,"usd":0.050006},"stage2":{"model":"claude-opus-4-6","input_tokens":6203,"output_tokens":2816,"usd":0.152122},"total_usd":0.525333,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":31830,"output_tokens":5170,"usd":0.08652},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8968,"output_tokens":4518,"usd":0.236685}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"Cathepsin L (CTSL) is required for SARS-CoV-2 entry into lung cells; Cas13d-mediated knockdown of Ctsl mRNA in mouse lungs decreased lung virus burden, reduced proinflammatory cytokines/chemokines, and extended survival of lethally infected mice, demonstrating a direct functional role of CTSL as a host protease facilitating viral infection.\",\n      \"method\": \"Cas13d nanosystem knockdown of Ctsl in vivo (mouse), viral burden measurement, cytokine profiling, survival analysis\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo KD with multiple orthogonal readouts (viral burden, cytokines, survival), strong mechanistic link\",\n      \"pmids\": [\"35879545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CTSL deficiency reduces internalization of the SARS-CoV-2 spike protein; spike protein treatment upregulates CTSL mRNA and protein levels and increases CTSL promoter activity in HeLa cells and iPSC-derived alveolarspheres, indicating CTSL is a functional mediator of spike protein endocytosis and is transcriptionally induced by the spike protein.\",\n      \"method\": \"CTSL knockout cells, spike protein internalization assay, CTSL promoter-reporter assay, mRNA/protein quantification\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined cellular phenotype and promoter reporter assay, single lab\",\n      \"pmids\": [\"38971996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A common promoter variant (C-171A, rs3118869) in the human CTSL1 gene disrupts a xenobiotic response element (XRE), altering transcription; the aryl hydrocarbon receptor complex (AHR:ARNT) augments CTSL1 transcription via this XRE, and the allele interacts with AHR:ARNT/dioxin stimulus to control expression; this promoter variant is associated with blood pressure in vivo.\",\n      \"method\": \"Promoter/luciferase reporter transfection, AHR:ARNT co-expression, dioxin treatment, human genetic association (two independent cohorts)\",\n      \"journal\": \"Journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro promoter reporter with functional mutagenesis replicated in two human populations; single lab\",\n      \"pmids\": [\"22871890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"lnc-CTSLP8 acts as a competitive endogenous RNA (ceRNA) by sponging miR-199a-5p, thereby upregulating CTSL1 expression and promoting autophagy and EMT in ovarian cancer cells; CTSL1 inhibitor treatment abrogated the oncogenic effects of lnc-CTSLP8.\",\n      \"method\": \"RNA immunoprecipitation, RNA pulldown, dual luciferase reporter assay, lentiviral OE/CRISPR KO, in vivo orthotopic tumor model\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RIP, pulldown, reporter, KO/OE, in vivo), single lab\",\n      \"pmids\": [\"33933142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTSL directly binds PDK1 and blocks NEDD4L-mediated ubiquitination of PDK1, thereby stabilizing PDK1 protein, sustaining AKT phosphorylation, and increasing PD-L1 expression on tumor cells — a non-proteolytic scaffolding function that drives immune evasion in HNSCC.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, genetic KD/OE in xenograft and immunocompetent mouse models, combination with anti-PD-1 therapy\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, ubiquitination assay, in vivo models; single lab\",\n      \"pmids\": [\"40961907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP20 deubiquitinates and stabilizes CTSL protein by competing with STUB1, which promotes CTSL ubiquitination and degradation; USP20-mediated CTSL stabilization promotes EMT and cancer stem cell renewal in HNSCC.\",\n      \"method\": \"Mass spectrometry identification of deubiquitinase, confocal colocalization, Co-IP, ubiquitination assay, KD/KO in vitro and in vivo\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification, Co-IP, ubiquitination assay, in vivo confirmation; single lab\",\n      \"pmids\": [\"41261048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Legumain drives the processing of CTSL (and other cathepsins) from single-chain to two-chain form; loss of legumain abrogates this processing and reduces nuclear CTSL levels in cell types where CTSL preferentially exists in the nucleus in its two-chain form; N-terminomics identified putative nuclear CTSL substrates involved in cell proliferation, cell cycle, inflammation, and ribosomal biogenesis.\",\n      \"method\": \"Chemical activity-based probes, immunoblots in LGMN−/− cells, N-terminomics (NICE pipeline), in vitro recombinant protease cleavage assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — activity-based probe profiling, KO cells, N-terminomics; preprint single lab but multiple orthogonal methods\",\n      \"pmids\": [\"bio_10.1101_2025.08.17.670765\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nervous system-specific double knockout of CtsB and CtsL in mice causes selective loss of specific Purkinje cell subtypes in the cerebellum, accumulation of ubiquitin-positive structures, impaired autophagy-lysosomal degradation, and neurodegeneration in thalamic nuclei, demonstrating that CTSL is essential for lysosomal proteostasis and survival of Purkinje cells.\",\n      \"method\": \"Conditional double-KO mice (Nestin-Cre), histology, electron microscopy, immunofluorescence, behavioral analysis\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — conditional KO with detailed cellular phenotype, EM ultrastructure, multiple markers; strong mechanistic link to autophagy-lysosomal pathway\",\n      \"pmids\": [\"40320169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Drug-induced nuclear trafficking of CTSL (nCTSL) is required for DNA damage response (cell cycle arrest and apoptosis) in ovarian cancer cells; clofarabine facilitates CTSL nuclear import via KPNB1, while CRM1/XPO1 mediates nuclear export; CTSL knockdown confers resistance to clofarabine + PARP inhibitor combination.\",\n      \"method\": \"CTSL KD in sensitive/resistant OC cell lines, ex vivo patient-derived ascites cultures, PDX models, nuclear fractionation, KPNB1/CRM1 inhibitor experiments\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with defined DDR phenotype, import/export mechanism identified, multiple model systems; preprint single lab\",\n      \"pmids\": [\"39868276\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTSL promotes autophagy in laryngeal cancer cells through activation of the IL6-JAK-STAT3 signalling pathway, as demonstrated by immunoprecipitation and autophagy marker analysis upon CTSL overexpression/knockdown.\",\n      \"method\": \"Immunoprecipitation, Western blotting, CCK8, wound healing, transwell invasion assay, IHC\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP/pathway activation, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"39893643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Transgenic overexpression of human CTSL in MMTV-PyMT breast cancer mice increases metastatic burden and produces a distinct lung metastasis proteome compared to CTSB overexpression, including elevated saposin and granulin levels, indicating CTSL has a specific and non-redundant role in remodeling the metastatic proteome.\",\n      \"method\": \"LC-MS/MS quantitative proteomics of lung metastases from transgenic mice (tgCTSL vs tgCTSB vs WT)\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative proteomics with biological replicates in transgenic animal model; single lab\",\n      \"pmids\": [\"29187882\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTSL (cathepsin L) is a lysosomal cysteine protease that: (1) cleaves the SARS-CoV-2 spike protein during endosomal entry to facilitate viral infection; (2) undergoes legumain-dependent processing from single-chain to two-chain form required for its nuclear localization, where it participates in DNA damage response and cell cycle regulation via KPNB1-mediated nuclear import and CRM1-mediated export; (3) is stabilized post-translationally by USP20-mediated deubiquitination competing with STUB1-mediated proteasomal degradation; (4) exerts a non-proteolytic scaffolding function by binding PDK1 to block NEDD4L-mediated ubiquitination, thereby sustaining AKT-PD-L1 signaling and immune evasion; (5) is essential for lysosomal proteostasis and autophagy-lysosomal degradation in Purkinje cells and other neurons; and (6) is transcriptionally regulated via an XRE in its promoter by the AHR:ARNT complex, linking environmental stimuli to its expression and downstream cardiovascular effects.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Crystal structure of human procathepsin L at 2.2 Å resolution revealed that the prosegment inhibits enzymatic activity through a globular N-terminal domain (three α-helices with a hydrophobic core) that packs against the enzyme surface, while the C-terminal portion occupies the substrate-binding cleft in reverse orientation to substrates.\",\n      \"method\": \"X-ray crystallography of a catalytic mutant of human procathepsin L\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure at 2.2 Å with functional interpretation of inhibitory mechanism\",\n      \"pmids\": [\"8896443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The serpin SCCA1 acts as a cross-class inhibitor of cathepsins K, L, and S at 1:1 stoichiometry with second-order rate constants ≥1×10⁵ M⁻¹ s⁻¹, forming stable covalent-like complexes via its reactive site loop, analogous to serpin–serine protease interactions.\",\n      \"method\": \"Kinetic analysis (in vitro enzyme inhibition assays) and SDS-PAGE detection of stable SCCA1–cathepsin complexes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with rigorous kinetic characterization\",\n      \"pmids\": [\"9548757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Secreted cathepsin L is responsible for generating endostatin from collagen XVIII with the predicted N-terminus at moderately acidic pH resembling the pericellular tumor milieu; metalloproteases produce larger fragments in a parallel pathway.\",\n      \"method\": \"Conditioned medium proteolysis assay, N-terminal amino acid sequencing, use of cathepsin L-specific inhibitors\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cell-free reconstitution identifying CTSL as sufficient protease for endostatin generation with N-terminal sequencing validation\",\n      \"pmids\": [\"10716919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A cathepsin L isoform lacking a signal peptide localizes to the nucleus during the G1-S transition and proteolytically processes the CDP/Cux transcription factor, regulating cell cycle progression; nuclear trafficking involves translation initiation at downstream AUG codons.\",\n      \"method\": \"Immunofluorescence imaging, activity-based probes for nuclear CTSL, ectopic expression in Cat L⁻/⁻ cells, in situ CDP/Cux processing assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including activity-based probes, genetic knockout rescue, and live-cell imaging establishing both localization and substrate\",\n      \"pmids\": [\"15099520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cathepsin L is required for SARS-CoV infection of ACE2-expressing cells; cathepsin L inhibitors block infection by SARS-CoV and retrovirus pseudotyped with SARS-CoV spike protein, and exogenous cathepsin L substantially enhances SARS-CoV S protein-mediated entry. HCoV-NL63, which uses the same ACE2 receptor, does not require cathepsin L, demonstrating distinct entry mechanisms for two ACE2-using coronaviruses.\",\n      \"method\": \"Pseudovirus infection assays, pharmacological inhibition of cathepsin L, exogenous cathepsin L expression in target cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (inhibitors, overexpression, pseudovirus) in same study, replicated with related PMID 16081529\",\n      \"pmids\": [\"16339146\", \"16081529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cathepsin L inhibitors block SARS-CoV infection; in a cell-free membrane fusion system, receptor engagement followed by cathepsin L proteolysis is sufficient to activate SARS-CoV spike-mediated membrane fusion, defining a unique three-step entry mechanism: receptor binding → conformational change → cathepsin L cleavage in endosomes.\",\n      \"method\": \"Cell-free membrane fusion assay, pharmacological inhibition of cathepsin L, lysosomotropic agents, SARS-CoV S protease treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cell-free reconstitution demonstrating cathepsin L is sufficient for spike activation and membrane fusion\",\n      \"pmids\": [\"16081529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cathepsin L is essential for endothelial progenitor cell (EPC)-mediated neovascularization: CathL-deficient mice showed impaired recovery after hind limb ischemia; CathL-deficient EPCs failed to home to ischemic tissue or promote neovascularization; forced CathL expression in mature endothelial cells conferred invasive and neovascularization capacity.\",\n      \"method\": \"CathL knockout mouse model, hind limb ischemia model, EPC infusion, in vitro matrix degradation/invasion assays, forced expression in endothelial cells\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mouse genetics plus gain-of-function rescue with defined phenotypic readouts\",\n      \"pmids\": [\"15665831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cathepsin L activates SARS-CoV spike protein membrane fusion function by cleaving the spike at the S1/S2 boundary region (upstream of the fusion peptide), mirroring where furin cleaves in other coronaviruses, thereby separating the receptor-binding from the fusion subunit.\",\n      \"method\": \"Cell-based fusion assays, cathepsin L cleavage mapping of spike protein truncation mutants\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct mapping of cleavage site with functional fusion readout\",\n      \"pmids\": [\"18562523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cytosolic cathepsin L cleaves essential regulators of podocyte actin dynamics, resulting in a motile podocyte phenotype and proteinuria, establishing CTSL as an enzymatic driver of podocyte dysfunction.\",\n      \"method\": \"Review synthesizing cell biological experiments including subcellular fractionation, CTSL activity assays, and podocyte actin dynamics readouts\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — synthesis of experimental findings from multiple studies; direct in-cell enzymatic evidence cited\",\n      \"pmids\": [\"19924101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A functional promoter variant C-171A (rs3118869) disrupts a xenobiotic response element (XRE) in the CTSL1 proximal promoter; AHR:ARNT complex with its ligand dioxin augments CTSL1 transcription, and the C-171A allele modulates this response, with genotype predicting blood pressure in two independent cohorts.\",\n      \"method\": \"Promoter/luciferase reporter transfection, co-expression of AHR:ARNT with dioxin, re-sequencing of CTSL1 locus, association analysis\",\n      \"journal\": \"Journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transfection reporter assay with mutagenesis and receptor co-expression, single lab\",\n      \"pmids\": [\"22871890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, and cathepsin L is critical for this entry process, as established using the SARS-CoV-2 S protein pseudovirus system.\",\n      \"method\": \"SARS-CoV-2 S pseudovirus infection assay, pharmacological inhibition (PIKfyve, TPC2, cathepsin L inhibitors)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pseudovirus system with pharmacological inhibitors, highly cited (2296 citations), replicated concept\",\n      \"pmids\": [\"32221306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTSL cleaves the SARS-CoV-2 spike protein and enhances virus entry; circulating CTSL is elevated in COVID-19 patients; SARS-CoV-2 pseudovirus infection increases CTSL expression in human cells and humanized ACE2-transgenic mice; CTSL overexpression enhances pseudovirus infection while knockdown reduces it; amantadine inhibits CTSL activity and prevents infection in vitro and in vivo.\",\n      \"method\": \"Pseudovirus infection assays, CTSL overexpression/knockdown, CTSL inhibitor treatment in vivo (ACE2-transgenic mice), ELISA measurement of circulating CTSL in patients\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (overexpression, knockdown, inhibitors, in vivo mouse model) with direct cleavage assay\",\n      \"pmids\": [\"33774649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In vivo Cas13d-mediated knockdown of lung Ctsl mRNA via a nanosystem prevents and treats SARS-CoV-2 infection in mice, extending survival of lethally infected mice and reducing lung viral burden, proinflammatory cytokines, and pulmonary inflammation.\",\n      \"method\": \"CRISPR-Cas13d mRNA knockdown delivered by nanosystem in vivo; mouse SARS-CoV-2 infection model; viral burden quantification; cytokine measurement\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function with defined phenotypic readouts, therapeutic rescue experiment\",\n      \"pmids\": [\"35879545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SARS-CoV-2 spike protein treatment of HeLa cells and iPSC-derived alveolarspheres induces upregulation of cathepsin L mRNA and protein levels in a time-dependent manner and increases cathepsin L promoter activity; knockout of cathepsin L reduces spike protein internalization, confirming a bidirectional relationship between CTSL and SARS-CoV-2 spike entry.\",\n      \"method\": \"Recombinant spike protein treatment, qRT-PCR, Western blot, CTSL promoter-reporter assay, CTSL knockout cell lines, spike protein internalization assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including KO and promoter assay, single lab\",\n      \"pmids\": [\"38971996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Legumain is required for processing of cathepsin L from single-chain to two-chain (mature) form; in legumain-deficient cells, CTSL remains in its single-chain form and nuclear CTSL levels are reduced in cell types where the double-chain form predominates in the nucleus. N-terminomics (NICE pipeline) identified putative nuclear substrates of CTSL involved in cell proliferation, cell cycle regulation, inflammation, and ribosomal biogenesis.\",\n      \"method\": \"Legumain-knockout (LGMN⁻/⁻) cells, activity-based probes (chemical), immunoblots, N-terminomics pipeline (NICE)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chemical activity-based probes + genetic KO + proteomics pipeline; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.08.17.670765\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTSL directly binds PDK1 in HNSCC cells, blocks NEDD4L-mediated ubiquitination of PDK1 (a non-proteolytic scaffolding function), thereby stabilizing PDK1, sustaining AKT phosphorylation, and increasing PD-L1 expression on tumor cells, driving immune evasion.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, xenograft and immunocompetent mouse models, anti-PD-1 combination therapy\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — reciprocal Co-IP with functional ubiquitination assay and in vivo validation, single lab\",\n      \"pmids\": [\"40961907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP20 deubiquitinates and stabilizes CTSL protein in HNSCC, competing with STUB1 which promotes CTSL ubiquitination and degradation; USP20-mediated CTSL stabilization drives epithelial-to-mesenchymal transition, cancer stem cell renewal, and chemoresistance.\",\n      \"method\": \"Broad-spectrum deubiquitinase inhibitor screen, mass spectrometry identification of USP20, confocal colocalization, Co-IP, ubiquitination assays, in vitro and in vivo tumor models\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (MS, Co-IP, ubiquitination assay, in vivo), single lab\",\n      \"pmids\": [\"41261048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nervous system-specific double knockout of CtsB and CtsL in mice causes selective loss of Purkinje cells (phospholipase C β4-positive, Zebrin II-negative) in cerebellar striped patterns, accumulation of ubiquitin-positive structures in perikarya and axons, reduction in synaptic vesicles, and neuronal loss in thalamic nuclei, demonstrating that CtsL (with CtsB) is essential for autophagy-lysosomal degradation in cerebellar Purkinje cells.\",\n      \"method\": \"Conditional double-knockout mice (Nestin-Cre; CTSBflox/flox; CTSLflox/flox), immunohistochemistry, electron microscopy, behavioral tests\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with multiple orthogonal readouts (behavior, histology, EM) demonstrating cell-type-specific requirement\",\n      \"pmids\": [\"40320169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Drug-induced nuclear trafficking of CTSL (via KPNB1-mediated import and CRM1/XPO1-mediated export regulation) is critical for the DNA damage response in ovarian cancer cells; nuclear CTSL mediates cell cycle arrest and apoptosis; CTSL knockdown confers resistance to the clofarabine + olaparib combination.\",\n      \"method\": \"CTSL knockdown, nuclear fractionation, KPNB1 import assay, CRM1 inhibition, patient-derived ovarian ascites ex vivo, PDX xenograft models\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell models and in vivo PDX validation; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"39868276\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Lysosomal cathepsins including cathepsin L are abnormally distributed in Alzheimer disease brains, accumulating in enlarged lysosomes of cortical neurons and appearing extracellularly in senile plaques, suggesting that lysosome dysfunction and liberation of cathepsins from degenerating neurons may contribute to amyloid precursor protein proteolysis and β-amyloid formation.\",\n      \"method\": \"Immunocytochemistry, immunoelectron microscopy, enzyme histochemistry in human brain tissue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization by immunohistochemistry with functional inference; replicated for multiple cathepsins\",\n      \"pmids\": [\"1837142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Transgenic overexpression of human CTSL in PyMT breast cancer mice increases metastatic burden and produces a distinct metastatic proteome signature compared with CTSB overexpression, including elevated saposin and granulin levels, demonstrating that CTSL has unique downstream substrate targets in vivo distinct from cathepsin B.\",\n      \"method\": \"LC-MS/MS quantitative proteomics of lung metastases from transgenic mice, hierarchical clustering\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative in vivo proteomics with three biological replicates and non-supervised clustering; single lab\",\n      \"pmids\": [\"29187882\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTSL encodes a lysosomal cysteine protease (cathepsin L) that is synthesized as an inactive proenzyme inhibited by its prosegment (established by crystal structure); it is activated by legumain-dependent processing to a two-chain mature form. In addition to its canonical lysosomal degradative role, CTSL is secreted at acidic pH to generate endostatin from collagen XVIII, traffics to the nucleus during G1-S transition (via a signal-peptide-deficient isoform imported through KPNB1) where it cleaves the CDP/Cux transcription factor to regulate cell cycle progression, is regulated post-translationally by USP20-mediated deubiquitination (stabilizing it) and STUB1-mediated ubiquitination (targeting it for degradation), and exerts non-proteolytic scaffolding functions by binding PDK1 to block NEDD4L-mediated ubiquitination, thereby sustaining AKT-PD-L1 signaling. In the context of coronavirus infection, CTSL is the endosomal protease that cleaves SARS-CoV/SARS-CoV-2 spike protein at the S1/S2 boundary to activate membrane fusion and virus entry, and SARS-CoV-2 spike protein in turn upregulates CTSL expression. CTSL is also required for endothelial progenitor cell-mediated neovascularization through matrix degradation, and for autophagy-lysosomal homeostasis in cerebellar Purkinje cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CTSL (cathepsin L) is a lysosomal cysteine protease with multifaceted roles in endosomal viral entry, lysosomal proteostasis, autophagy, nuclear DNA damage response, and tumor progression. As a host protease, CTSL cleaves the SARS-CoV-2 spike protein to facilitate viral internalization, and its in vivo knockdown reduces lung viral burden and inflammatory cytokines [PMID:35879545, PMID:38971996]. Beyond lysosomal proteolysis, CTSL undergoes legumain-dependent processing to a two-chain form that enables KPNB1-mediated nuclear import, where it participates in cell cycle regulation and DNA damage response [PMID:39868276]; in neurons, CTSL is essential for autophagy-lysosomal degradation and Purkinje cell survival [PMID:40320169]. CTSL also exerts a non-proteolytic scaffolding function by binding PDK1 to block NEDD4L-mediated ubiquitination, thereby sustaining AKT-PD-L1 signaling and immune evasion, while its own stability is regulated by USP20-mediated deubiquitination opposing STUB1-dependent degradation [PMID:40961907, PMID:41261048].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying how CTSL transcription is environmentally regulated established that the AHR:ARNT complex activates CTSL expression via a xenobiotic response element in its promoter, linking environmental stimuli to CTSL levels and downstream cardiovascular phenotypes.\",\n      \"evidence\": \"Promoter-reporter assays with AHR:ARNT co-expression and dioxin treatment, replicated genetic association in two human cohorts\",\n      \"pmids\": [\"22871890\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether AHR:ARNT regulation of CTSL is operative in non-cardiovascular tissues\",\n        \"No chromatin-level confirmation (e.g., ChIP) of AHR:ARNT occupancy at the endogenous CTSL promoter\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that CTSL has a specific, non-redundant role in tumor metastasis distinct from CTSB, transgenic CTSL overexpression in breast cancer mice increased metastatic burden and produced a unique lung metastasis proteome including elevated saposin and granulin levels.\",\n      \"evidence\": \"LC-MS/MS quantitative proteomics of lung metastases from MMTV-PyMT transgenic mice overexpressing CTSL vs CTSB\",\n      \"pmids\": [\"29187882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific CTSL substrates driving metastatic proteome remodeling not identified\",\n        \"Whether the non-redundant metastatic role is proteolytic or scaffolding-based is unclear\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealing a post-transcriptional regulatory axis, lnc-CTSLP8 was shown to sponge miR-199a-5p to upregulate CTSL expression, thereby promoting autophagy and EMT in ovarian cancer, with CTSL inhibition reversing these effects.\",\n      \"evidence\": \"RIP, RNA pulldown, dual luciferase reporter, CRISPR KO/OE, orthotopic tumor model in ovarian cancer cells\",\n      \"pmids\": [\"33933142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether miR-199a-5p–CTSL axis operates outside ovarian cancer\",\n        \"Direct CTSL substrates mediating autophagy and EMT not identified\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing CTSL as a druggable host factor for SARS-CoV-2, in vivo Cas13d-mediated knockdown of Ctsl in mouse lungs reduced viral burden, suppressed proinflammatory cytokines, and extended survival of lethally infected animals.\",\n      \"evidence\": \"Cas13d nanosystem knockdown in vivo, viral burden quantification, cytokine profiling, survival analysis in mice\",\n      \"pmids\": [\"35879545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether CTSL inhibition affects other coronaviruses with similar entry mechanisms\",\n        \"Relative contribution of CTSL vs TMPRSS2 in different human cell types not resolved in this study\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extending the viral entry mechanism, CTSL deficiency was shown to reduce spike protein internalization, and the spike protein itself transcriptionally upregulates CTSL, establishing a positive feedback loop between virus and host protease.\",\n      \"evidence\": \"CTSL KO cells, spike internalization assay, CTSL promoter-reporter assay in HeLa and iPSC-derived alveolarspheres\",\n      \"pmids\": [\"38971996\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Transcription factor(s) mediating spike-induced CTSL promoter activation not identified\",\n        \"Whether this feedback loop operates in primary airway epithelium in vivo\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealing that CTSL has a non-proteolytic scaffolding function, CTSL was shown to bind PDK1 and block NEDD4L-mediated ubiquitination, thereby stabilizing PDK1, sustaining AKT phosphorylation, and upregulating PD-L1 for immune evasion in HNSCC.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, genetic KD/OE in xenograft and immunocompetent mouse models with anti-PD-1 combination\",\n      \"pmids\": [\"40961907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the scaffolding function requires specific CTSL domains independent of the active site\",\n        \"Generalizability of the non-proteolytic role beyond HNSCC\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying the post-translational stability mechanism for CTSL itself, USP20 was found to deubiquitinate and stabilize CTSL by opposing STUB1-mediated proteasomal degradation, with functional consequences for EMT and cancer stemness.\",\n      \"evidence\": \"Mass spectrometry identification of USP20, confocal colocalization, Co-IP, ubiquitination assays, KD/KO in vitro and in vivo\",\n      \"pmids\": [\"41261048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific ubiquitin chain types on CTSL cleaved by USP20 not defined\",\n        \"Whether USP20-CTSL axis operates in non-cancer contexts\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Establishing that CTSL is essential for neuronal lysosomal proteostasis, nervous system-specific double knockout of CtsB and CtsL caused Purkinje cell loss, ubiquitin-positive accumulations, and impaired autophagy-lysosomal degradation in mice.\",\n      \"evidence\": \"Conditional double-KO mice (Nestin-Cre), histology, electron microscopy, immunofluorescence, behavioral analysis\",\n      \"pmids\": [\"40320169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Individual contribution of CTSL vs CTSB to Purkinje cell survival not resolved by double-KO design\",\n        \"Specific CTSL substrates whose accumulation drives neurodegeneration not identified\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Elucidating CTSL nuclear trafficking, legumain-dependent processing to a two-chain form was shown to be required for nuclear localization, and KPNB1-mediated nuclear import of CTSL was required for DNA damage response and cell cycle arrest in ovarian cancer cells.\",\n      \"evidence\": \"(preprint) LGMN-KO cells with activity-based probes and N-terminomics; (preprint) CTSL KD with nuclear fractionation, KPNB1/CRM1 inhibitors in OC cell lines and PDX models\",\n      \"pmids\": [\"bio_10.1101_2025.08.17.670765\", \"39868276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Both studies are preprints awaiting peer review\",\n        \"Nuclear CTSL substrates identified by N-terminomics require individual validation\",\n        \"Whether nuclear CTSL function is proteolytic or scaffolding in the DDR context\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the full catalog of nuclear CTSL substrates, the structural basis for the non-proteolytic PDK1-binding function, whether the USP20/STUB1 regulatory axis controls CTSL in non-cancer settings, and the individual contribution of CTSL (vs CTSB) to neuronal lysosomal proteostasis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No crystal structure of CTSL in complex with PDK1 or nuclear import machinery\",\n        \"Systematic identification of non-redundant CTSL substrates in lysosomes vs nucleus lacking\",\n        \"Relative importance of proteolytic vs scaffolding functions across tissue types undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 7, 10]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 8]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [3, 7, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PDK1\",\n      \"USP20\",\n      \"STUB1\",\n      \"NEDD4L\",\n      \"KPNB1\",\n      \"LGMN\",\n      \"CTSB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Cathepsin L (CTSL) is a lysosomal cysteine endopeptidase with broad roles in protein turnover, extracellular matrix remodeling, cell cycle regulation, viral entry, and neuronal homeostasis. Synthesized as an inactive proenzyme whose prosegment occupies the active-site cleft in reverse orientation to block catalysis [PMID:8896443], CTSL is activated by legumain-dependent processing to a two-chain mature form and traffics not only to lysosomes but also to the nucleus via a signal-peptide-deficient isoform imported through KPNB1, where it cleaves the CDP/Cux transcription factor to promote G1-S progression [PMID:15099520, PMID:39868276]. CTSL is the principal endosomal protease that cleaves the SARS-CoV and SARS-CoV-2 spike proteins at the S1/S2 boundary to activate membrane fusion and viral entry, a function validated by pharmacological inhibition, genetic knockout, and in vivo Cas13d-mediated knockdown [PMID:16081529, PMID:32221306, PMID:35879545]. Beyond its proteolytic activities—including secreted cleavage of collagen XVIII to generate endostatin [PMID:10716919] and regulation of podocyte actin dynamics [PMID:19924101]—CTSL exerts a non-proteolytic scaffolding function by binding PDK1 to block NEDD4L-mediated ubiquitination, sustaining AKT–PD-L1 signaling in head and neck cancer [PMID:40961907].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Early evidence that cathepsin L redistributes from lysosomes in disease states established that CTSL is not confined to a housekeeping lysosomal role but may contribute to neurodegeneration through aberrant localization and extracellular release.\",\n      \"evidence\": \"Immunocytochemistry and immunoelectron microscopy of Alzheimer disease brain tissue\",\n      \"pmids\": [\"1837142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative localization only; no causal evidence that CTSL itself drives amyloid pathology\", \"No loss-of-function or gain-of-function test in neurodegeneration models at this stage\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The crystal structure of procathepsin L resolved how the prosegment inhibits enzymatic activity, providing a structural basis for understanding zymogen activation and the molecular switch controlling CTSL protease function.\",\n      \"evidence\": \"X-ray crystallography of catalytic-mutant human procathepsin L at 2.2 Å resolution\",\n      \"pmids\": [\"8896443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure did not reveal which protease(s) remove the prosegment in vivo\", \"No information on how differential isoforms or trafficking alter activation\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of SCCA1 as a cross-class serpin inhibitor of cathepsin L defined an endogenous regulatory axis controlling CTSL activity at 1:1 stoichiometry with kinetics rivaling classical serpin–serine protease pairs.\",\n      \"evidence\": \"In vitro kinetic analysis and SDS-PAGE detection of stable SCCA1–cathepsin L complexes\",\n      \"pmids\": [\"9548757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context of SCCA1–CTSL interaction in specific tissues not established\", \"Whether SCCA1 inhibits nuclear or secreted CTSL pools was not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that secreted cathepsin L generates endostatin from collagen XVIII at acidic pH established an extracellular, anti-angiogenic substrate-processing role distinct from lysosomal housekeeping.\",\n      \"evidence\": \"Conditioned medium proteolysis assay with cathepsin L-specific inhibitors and N-terminal sequencing of the product\",\n      \"pmids\": [\"10716919\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of CTSL-generated endostatin versus metalloprotease-generated fragments not resolved\", \"Tumor microenvironment pH dependence not directly measured in situ\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that a signal-peptide-deficient CTSL isoform localizes to the nucleus during G1-S and cleaves CDP/Cux revealed a moonlighting nuclear protease function regulating cell cycle gene expression, fundamentally expanding the functional repertoire of CTSL beyond lysosomes.\",\n      \"evidence\": \"Activity-based probes, immunofluorescence, and CDP/Cux processing assay in CathL-knockout and rescue cells\",\n      \"pmids\": [\"15099520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of nuclear substrates unknown at this point\", \"Mechanism of nuclear import not yet identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Multiple studies established CTSL as the critical endosomal protease for SARS-CoV spike-mediated entry, with a cell-free reconstitution proving that receptor binding followed by CTSL cleavage is sufficient to trigger membrane fusion—defining a unique three-step entry mechanism.\",\n      \"evidence\": \"Pseudovirus infection assays, exogenous CTSL expression, pharmacological inhibition, and cell-free membrane fusion reconstitution\",\n      \"pmids\": [\"16339146\", \"16081529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise cleavage site on SARS-CoV spike not yet mapped\", \"Relative contribution of CTSL versus cathepsin B in different cell types not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"In vivo loss-of-function studies showed that cathepsin L is essential for endothelial progenitor cell homing and neovascularization after ischemia, establishing a non-redundant role in tissue repair through matrix degradation.\",\n      \"evidence\": \"CathL-knockout mice, hind limb ischemia model, EPC infusion, and forced CTSL expression in endothelial cells\",\n      \"pmids\": [\"15665831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific extracellular matrix substrates cleaved by CTSL in this context not identified\", \"Whether CTSL acts cell-autonomously or through paracrine substrate release not distinguished\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapping the CTSL cleavage site on SARS-CoV spike to the S1/S2 boundary resolved where the protease acts, showing it separates the receptor-binding and fusion subunits analogously to furin cleavage in other coronaviruses.\",\n      \"evidence\": \"Cathepsin L cleavage mapping using spike truncation mutants with cell-based fusion readout\",\n      \"pmids\": [\"18562523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same site is used for SARS-CoV-2 spike was not yet tested\", \"Structural basis for CTSL recognition of the spike cleavage site not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extension of the SARS-CoV paradigm to SARS-CoV-2 confirmed that cathepsin L is critical for endosomal entry of the pandemic coronavirus, validating CTSL as a host-directed therapeutic target.\",\n      \"evidence\": \"SARS-CoV-2 S pseudovirus infection assays with cathepsin L inhibitors in 293/hACE2 cells\",\n      \"pmids\": [\"32221306\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pseudovirus system may not fully recapitulate live virus biology\", \"Cell-type-specific dependence (e.g. TMPRSS2 co-expression) not fully parsed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Bidirectional regulation was uncovered: SARS-CoV-2 spike upregulates CTSL expression, and elevated circulating CTSL in COVID-19 patients creates a positive feedback loop enhancing viral entry, validated by in vivo amantadine inhibition.\",\n      \"evidence\": \"Pseudovirus assays, CTSL overexpression/knockdown, ELISA in patient sera, ACE2-transgenic mouse infection with amantadine treatment\",\n      \"pmids\": [\"33774649\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which spike upregulates CTSL transcription not defined\", \"Amantadine's specificity for CTSL versus off-target effects not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"In vivo Cas13d-mediated knockdown of Ctsl mRNA prevented and treated SARS-CoV-2 infection in mice, providing genetic proof-of-concept for CTSL as a therapeutic target beyond pharmacological inhibition.\",\n      \"evidence\": \"CRISPR-Cas13d nanosystem delivery to mouse lungs, live SARS-CoV-2 challenge, survival and viral burden quantification\",\n      \"pmids\": [\"35879545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety and off-target effects of Ctsl knockdown in lung not assessed\", \"Whether compensatory cathepsins are upregulated not examined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Transgenic CTSL overexpression in breast cancer mice produced a metastatic proteome signature distinct from cathepsin B, demonstrating that CTSL has unique in vivo substrate specificity relevant to metastasis.\",\n      \"evidence\": \"LC-MS/MS quantitative proteomics of lung metastases from CTSL-transgenic PyMT mice\",\n      \"pmids\": [\"29187882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cleavage of identified substrates (saposin, granulin) by CTSL not biochemically verified\", \"Whether the metastatic phenotype is protease-activity-dependent was not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Detailed promoter analysis confirmed that SARS-CoV-2 spike directly increases CTSL promoter activity and that CTSL knockout reduces spike internalization, mechanistically closing the positive feedback loop between spike and CTSL.\",\n      \"evidence\": \"Spike protein treatment, CTSL promoter-reporter assay, CTSL knockout cell lines, iPSC-derived alveolarspheres\",\n      \"pmids\": [\"38971996\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factor mediating spike-induced CTSL promoter activation not identified\", \"Single lab; independent replication needed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Post-translational regulation of CTSL was elucidated: USP20 deubiquitinates and stabilizes CTSL while STUB1 promotes its ubiquitination and degradation, with this balance driving EMT and chemoresistance in HNSCC.\",\n      \"evidence\": \"DUB inhibitor screen, mass spectrometry, Co-IP, ubiquitination assays, in vivo tumor models\",\n      \"pmids\": [\"41261048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination sites on CTSL not mapped\", \"Whether USP20/STUB1 regulation operates in non-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A non-proteolytic scaffolding function was discovered: CTSL binds PDK1 and blocks NEDD4L-mediated ubiquitination to sustain AKT–PD-L1 signaling, revealing a protease-independent mechanism for immune evasion in HNSCC.\",\n      \"evidence\": \"Reciprocal Co-IP, ubiquitination assays, xenograft and immunocompetent mouse models with anti-PD-1 therapy\",\n      \"pmids\": [\"40961907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the scaffolding function requires a catalytically dead form or coexists with active enzyme not resolved\", \"Generalizability beyond HNSCC not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Conditional double knockout of CtsB and CtsL in the nervous system demonstrated that CTSL is essential for autophagy-lysosomal homeostasis in cerebellar Purkinje cells, with cell-type-selective vulnerability (Zebrin II-negative, PLCβ4-positive neurons).\",\n      \"evidence\": \"Nestin-Cre conditional double-knockout mice, immunohistochemistry, electron microscopy, behavioral testing\",\n      \"pmids\": [\"40320169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contribution of CTSL versus CTSB cannot be separated in the double knockout\", \"Whether CTSL protects through specific substrate cleavage or bulk autophagosome clearance is not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Legumain was identified as the protease required for processing single-chain CTSL to the two-chain mature form, and N-terminomics identified putative nuclear CTSL substrates involved in proliferation, cell cycle, and ribosomal biogenesis, expanding the nuclear substrate repertoire. (preprint)\",\n      \"evidence\": \"(preprint) Legumain-knockout cells, activity-based probes, immunoblots, NICE N-terminomics pipeline\",\n      \"pmids\": [\"bio_10.1101_2025.08.17.670765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint; not yet peer-reviewed\", \"Identified nuclear substrates are putative; direct cleavage validation required\", \"Whether single-chain CTSL is catalytically active in the nucleus not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Drug-induced nuclear CTSL import via KPNB1 was shown to mediate DNA damage response and apoptosis in ovarian cancer, and CTSL knockdown conferred drug resistance, identifying the nuclear import pathway and a therapeutic vulnerability. (preprint)\",\n      \"evidence\": \"(preprint) CTSL knockdown, nuclear fractionation, KPNB1 import assay, CRM1 inhibition, PDX models\",\n      \"pmids\": [\"39868276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint; not yet peer-reviewed\", \"Whether CTSL acts on DNA damage repair substrates directly or indirectly not resolved\", \"Generalizability beyond clofarabine/olaparib combination not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: the full catalog of nuclear CTSL substrates, the structural basis for CTSL's non-proteolytic scaffolding of PDK1, whether the CTSL ubiquitination-deubiquitination regulatory circuit (USP20/STUB1) operates broadly beyond HNSCC, and the individual contribution of CTSL versus CTSB to Purkinje cell survival.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No comprehensive nuclear substrate validation exists\", \"Structural basis of CTSL–PDK1 scaffolding interaction not determined\", \"Individual CTSL versus CTSB neuronal functions require single-knockout conditional models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 7, 8, 11]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3, 7, 8]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 1, 17, 19]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 14, 18]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 5, 10, 11]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 14, 16]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 5, 10, 11, 12]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 5, 10, 11, 12, 15, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SERPINB3\",\n      \"PDK1\",\n      \"NEDD4L\",\n      \"USP20\",\n      \"STUB1\",\n      \"KPNB1\",\n      \"LGMN\",\n      \"CUX1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}